期刊
FUTURE ONCOLOGY
卷 16, 期 18, 页码 1235-1244出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-0184
关键词
chemoradiation; head and neck cancer; immune checkpoint blockade; PD-1; PD-L1; pembrolizumab
类别
资金
- Merck Sharp Dohme Corp.
- Debiopharm
- Merck Sharp Dohme
- Pfizer
- Bayer
- AstraZeneca
- Eisai
- Bristol-Myers Squibb
- Ono Pharmaceutical
- Rakuten Medical
- Novartis
- Merck Serono
- Roche
- Regeneron
- GlaxoSmithKline
- Sanofi
- Boehringer Ingelheim
- Oncolys BioPharma
- Replimune
- BeiGene
- Roche/Genentech
- Karyopharm
- AstraZeneca/Medimmune
- Celgene
- Astellas
- AbbVie
- Symphogen
- Intensity Therapeutics
- Mirati Therapeutics
- Shattuck Labs
- Avid Radiopharmaceuticals
Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with or without chemotherapy. The immune checkpoint inhibitor pembrolizumab has previously demonstrated antitumor activity in recurrent and/or metastatic HNSCC in large Phase III trials. For patients with locally advanced disease, Phase Ib data on the use of pembrolizumab in combination with chemoradiation have shown the approach to be safe and feasible. We describe here the design and rationale for KEYNOTE-412, a randomized, double-blind, Phase III trial investigating pembrolizumab or placebo administered concurrently with CRT and as maintenance treatment in patients with locally advanced HNSCC. Clinical Trial Registration: NCT03040999 (ClinicalTrials.gov).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据